Therapeutic Drug Monitoring · 1999 · 10 citations · 13 references
PharmacyPharmaceutical AnalysisPharmacologyAnalytical ChemistryAnalytical ToxicologyChromatographic AnalysisAnalytical ChromatographyChromatographic Analysis Of PharmaceuticalsChromatographyGas ChromatographyInstrumental AnalysisMetabolite ExtractionBuspirone PharmacologyGas Chromatography-mass SpectrometryInternal Standard AnalysisNitrogen-phosphorus Detection
Two separate gas chromatographic methods for the determination of buspirone and its active metabolite, 1-(2-pyrimidinyl)-piperazine (1-PP) in human plasma are described. Both procedures involve solid-phase extraction (the packing material of the cartridges used was C8 for buspirone and a mixed-mode sorbent for 1-PP), injection of the sample into a gas chromatograph equipped with a fused-silica capillary column and a nitrogen-phosphorus detector, and analysis with temperature programming (from 220 degrees C to 285 degrees C for buspirone and from 138 degrees C to 285 degrees C for 1-PP). The coating material of the analytical column was 5% diphenyl dimethyl silicone for buspirone and 50% diphenyl dimethyl silicone for 1-PP. Zolpidem was used as an internal standard in the buspirone assay and 1-phenylpiperazine in the 1-PP assay. Recovery of buspirone and 1-PP averaged 98% and 89%, respectively, and the limit of quantification was 0.2 ng/mL for both compounds. The between-run coefficients of variation ranged from 3.2% to 9.4% and from 2.9% to 8.6% for samples spiked with three different concentrations of buspirone and 1-PP, respectively. The suitability of these assays for pharmacokinetic studies was shown by analyzing timed plasma samples from volunteers after ingestion of a single therapeutic dose of buspirone (10 mg).
13
Yvan Gaillard, Jean-Pierre Gay-Montchamp, Michel Ollagnier · Journal of Chromatography B Biomedical Sciences and Applications · 1993 · 100 citations
David J. Greenblatt, Jerold S. Harmatz, Terry A. Gouthro et al. · Clinical Pharmacology & Therapeutics · 1994 · 58 citations